MiNK Therapeutics, Inc.

NASDAQ:INKT

0.71 (USD) • At close November 1, 2024
Bedrijfsnaam MiNK Therapeutics, Inc.
Symbool INKT
Munteenheid USD
Prijs 0.709
Beurswaarde 28,033,640
Dividendpercentage 0%
52-weken bereik 0.57 - 1.9
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jennifer S. Buell Ph.D.
Website https://minktherapeutics.com

An error occurred while fetching data.

Over MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases,

Vergelijkbare Aandelen

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

3.73 USD

Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

CRVS

9.1 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

2.23 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

7.81 USD

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

SYRS

2.265 USD

Catalyst Biosciences, Inc. logo

Catalyst Biosciences, Inc.

CBIO

0.511 USD

Venus Concept Inc. logo

Venus Concept Inc.

VERO

0.43 USD

Freeline Therapeutics Holdings plc logo

Freeline Therapeutics Holdings plc

FRLN

6.49 USD

Accelerate Diagnostics, Inc. logo

Accelerate Diagnostics, Inc.

AXDX

1.93 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)